A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus.
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Pimodivir (Primary)
- Indications Influenza A virus infections
- Focus Therapeutic Use
- 04 Mar 2013 Primary endpoint 'Viral-shedding' has been met, according to a Vertex Pharmaceuticals media release.
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jul 2012 Results are expected before the end of 2012.